MIT engineers build virus-based nanoparticles for custom cancer vaccines

Engineers at the Massachusetts Institute of Technology have designed a new type of nanoscale delivery vehicle using a modified virus. This platform could eventually help create customized vaccines to target individual tumors in patients. The backbone of the system relies on a harmless virus known as the M13 bacteriophage, which naturally forms long, thread-like structures.

Customizing Viral Nanoparticles

The research team modified the protein shell of the virus by attaching specific cancer antigens, which are proteins that trigger an immune response. By altering the genetic sequence of the virus, the scientists learned to control the exact density and spacing of these antigens along the surface of the nanofiber. Tests showed that adjusting this density is critical for generating a strong immune response from the body.

Promising Results in Mice

In laboratory tests involving mice, the team demonstrated that the nanoparticle vaccines could successfully prevent the development of specific tumors, including melanoma and colon cancer. The virus itself also acts as an adjuvant, a substance that boosts the body’s immune reaction, reducing the need for outside additives. Researchers hope to adapt this modular platform to treat various forms of cancer in the future.